TNIB >>> ACQUIRES PENN STATE RESEARCH FOUNDATION PATENTZZZ
TNI BioTech Acquires Exclusive License To The Portfilio Of Patents Of Dr Ian S. Zagon, Dr. Patricia J. McLauglin And Dr. Jill Smith From The Penn State Research Foundation
BETHESDA, Md., Feb. 1, 2013 /PRNewswire/ -- TNI BioTech, Inc. (TNIB) has signed an exclusive licensing agreement for all of the intellectual property developed at Pennsylvania State by Dr. Ian S. Zagon, Dr. Patricia J. McLaughlin and Dr. Jill P. Smith for the treatment of cancer. The patents cover methods and formulations related to the treatment and prevention of cancers, particularly gastrointestinal cancer. More specifically, the present inventions describe the use of drugs that interact with opioid receptors (naltrexone, naloxone and the pentapeptide growth factor Met-enkephalin) to inhibit and arrest the growth of cancer. Such efficacy has been discovered to be partially due to the functional manipulation of the zeta opioid receptor through exogenous and endogenous Met-enkephalin. This receptor has been determined to be present in a variety of cancers, including pancreatic and colon cancer.
As part of this agreement, TNI BioTech, Inc. is working to acquire the orphan drug designation (IND), and clinical data set from Dr. Jill Smith.
Dr. Ronald Herberman, Chief Medical Officer and Senior Vice President for Research and Development stated, "TNI BioTech is extremely pleased to acquire the exclusive rights to the patent portfolio of the Penn State Research Foundation. Based on the pioneering work of Drs. Ian S. Zagon, Dr. Patricia J. McLaughlin and Dr. Jill P. Smith, these patents are related to the therapeutic efficacy and mechanism of action of Met-enkephalin, referred to as opioid growth factor. These patent acquisitions will help TNI BioTech develop our pipeline for therapy of cancer in conjunction with our other cancer therapies revolving around Met-enkephalin."
Summary of Clinical Trial on the Benefits of OGF in the Treatment of Pancreatic Cancer
In a prospective phase II open-labeled clinical trial performed by Dr. Jill Smith and her colleagues in the Departments of Medicine, Public Health Sciences, Pathology, and Neurosciences and Anatomy at the Pennsylvania State University School of Medicine in Hershey, PA, patients with very advanced pancreatic cancer were treated. These patients had failed prior chemotherapy regimens and were either treated weekly with opioid growth factor (OGF) or entered a hospice program.
Results: Clinical benefit response was experienced by 53% of OGF-treated patients compared to historical controls of 23.8% and 4.8% for gemcitabine and 5-fluorouracil (5-FU), respectively. Of the OGF-treated patients surviving more than eight weeks, 62% showed either a decrease or stabilization in tumor size by computed tomography. The median survival time for the OGF-treated patients was three times that of the untreated hospice patients (65.5 versus 21 days, p < 0.001). No adverse effects on hematologic or chemistry parameters were noted, and quality of life surveys suggested improvement with OGF.
Limitations: Measurements other than survival were not allowed in the control hospice patients, and clinical benefit comparisons were made to historical controls.
Conclusion: OGF biotherapy improves the clinical benefit and prolongs survival in patients with pancreatic cancer by stabilizing disease or slowing progression. The effects of OGF did not adversely alter the patients' quality of life. The use of OGF biotherapy at earlier stages of disease or in combination with chemotherapeutic agents may further improve the outcome of this malignancy.
About TNI BioTech, Inc.
TNI BioTech, Inc., is a biotech company working to combat chronic, life-threatening diseases through the activation modulating the body's immune system using our patented immunotherapy. Our products and immunotherapy technologies are designed to harness the power of the immune system to improve the treatment of cancer, infections such as HIV/AIDS, chronic inflammatory diseases, and autoimmune diseases.
TNI BioTech's proprietary technology, therapies and patents include the treatment of a wide range of cancers. Their most advanced clinical program involves immunotherapy with Methionine Enkephalin (MENK) also termed Opioid Growth Factor (OGF), which has been shown to stimulate the immune system even in patients with advanced cancer.
Even though TNI BioTech considers any condition that results in altered-immune response a target for investigation, they plan to pursue additional investigations for low dose naltrexone and/or MENK as valuable candidates in the treatment of the following:
Autoimmune states such as Crohn's disease, multiple sclerosis and rheumatoid arthritis
As an adjunct in cancer patients undergoing chemotherapy, radiation treatments or surgery
As an adjunct to antibiotics in the treatment of a variety of infectious diseases, including patients with HIV or patients with AIDS, in combination with retroviral drug therapy
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS: This press release includes various "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which represent the Company's expectations or beliefs concerning future events. Statements containing expressions such as "believes," "anticipates," "intends," or "expects," used in the Company's press releases and in Disclosure Statements and Reports filed with the Over The Counter Markets through the OTC Disclosure and News Service are intended to identify forward-looking statements. All forward-looking statements involve risks and uncertainties. Although the Company believes its expectations are based upon reasonable assumptions within the bounds of its knowledge of its business and operations, there can be no assurances that actual results will not differ materially from expected results. The Company cautions that these and similar statements included in this report are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date thereof. The Company undertakes no obligation to publicly release any revisions to such forward-looking statements to reflect events or circumstances after the date hereof.
See http://www.tnibiotech.com for more information.
Contact: Global Investment Media
Phone: 310-353-6277
TNIB ACQUIRES PENN STATE RESEARCH FOUNDATION PATENTZZZ
Top 10 Most Recent News Articles
Prospera’s DFW Culture Win Matters Beyond the Plaque
Employee survey ballots rarely make pulses race, but this one deserves more than a lazy shrug. Prospera Financial Services has landed on The Dallas Morning News’ 2026 Top Workplaces DFW list for a second consecutive year, placing in the Top Small Workplaces category. For a boutique independent broker-dealer, that is not meaningless wall décor. The people doing the...
Continue Reading
Subsplash Builds a Broader Church Software Stack in 2026
Church software has spent too many years behaving like a junk drawer, and Subsplash is plainly trying to replace it with one working system. The company used its November 18 Product Event in Dallas to show off releases from 2026 and preview two additions: Communications, due in December, and Subsplash Intelligence, targeted for early 2027. A Serious Push Beyond the Church...
Continue Reading
D-Wave Investors Face December 15 Lead Plaintiff Clock
Quantum dreams met a very earthly spreadsheet problem at D-Wave this summer. The proposed securities class action against D-Wave Quantum Inc. puts a hard date on the issue for investors who bought shares between February 26 and August 25, 2026: December 15, 2026 is the deadline to seek lead-plaintiff status. That does not mean every holder needs to march into court. It...
Continue Reading
Six LIFE Photographers Bring History Into Florida Focus
Seventy photographs can make a pretty loud argument when the historical record has been this lopsided. The Ashley Gibson Barnett Museum of Art at Florida Southern College has brought LIFE: Six Women Photographers to Lakeland, and it deserves more than the usual polite nod given to a traveling museum show. Open since November 14, 2026, and running through March 7, 2027,...
Continue Reading
Wenge AI Removes a Small Friction Point for ScienceOra
Scientific software rarely loses users because the underlying model is too clever; it loses them because getting through the front door is a nuisance. Wenge AI has addressed that unglamorous problem by adding Google and Apple sign-in options to the international version of ScienceOra, its AI-powered research and decision-support platform. This is not the sort of...
Continue Reading
CITGO Sign Return Caps Kenmore's Careful Rebuild Work
Thirty feet upward and 120 feet eastward is not the sort of move that usually stops a city in its tracks, yet Boston’s CITGO Sign was never merely rooftop hardware. Its public relighting in Kenmore Square marks the final phase of the redevelopment at 660 Beacon Street, and the real accomplishment is less flashy than the lights: a beloved, federally landmarked object...
Continue Reading
APEC's Shenzhen Signal Is Bigger Than a Two-Day Summit
Shenzhen spent two days trying to turn regional anxiety into a workable agenda. The APEC CEO Summit 2026, held November 17 and 18 at the Qianhai International Convention Center, brought together more than 2,000 political and business leaders from all 21 APEC economies and 13 economies outside the group. That is a serious room, not a ceremonial photo line. Still, investors...
Continue Reading
SHEIN's EU Training Push Targets Seller Compliance Gaps
Chemicals buried in a cheap handbag or kids' accessory can wreck a marketplace's credibility faster than any glossy campaign can repair it. That is the uncomfortable backdrop to SHEIN and SPEAC's November 19 session on EU chemical-safety rules for marketplace sellers. This was not a fashion trend webinar; it was a practical warning about high-risk substances, regulatory...
Continue Reading
GreenTree Faces Softer Rooms, Debt and NYSE Deadline
A hotel operator can post positive earnings and still leave shareholders with a nasty headache, and GreenTree's third quarter is that kind of report. NYSE:GHG produced RMB243.0 million in revenue, down 22.2% from a year earlier, while net income slipped to RMB49.3 million from RMB59.0 million. This was not a one-line stumble. Room pricing, occupancy, franchise economics...
Continue Reading
Epilepsy Campaign Puts Patient Voices Before Investors
An epilepsy diagnosis can turn ordinary family routines into a maze overnight, which is why awareness work deserves more than the usual polite nod and a colored ribbon. Mediaplanet's national Epilepsy Awareness campaign, launched November 20, 2026, brings the subject into a USA TODAY print insert and related digital coverage during Epilepsy Awareness Month. That reach...
Continue ReadingTop 5 Most Recently Viewed Articles
NANO Nuclear Energy Partners with Cambridge Atom Works for ODIN Sale
NANO Nuclear Energy Partners with Cambridge Atom Works for ODIN Sale NANO Nuclear Energy Inc. has made a pivotal move by signing a letter of intent to sell its innovative ODIN™ low-pressure coolant reactor technology. This strategic decision not only signifies NANO Nuclear's commitment to optimizing their technology portfolio but also enables a sharper focus on their...
Continue Reading
Project C.U.R.E. and Microsoft: Transforming Global Health Access
Transforming Global Healthcare Through Innovative Partnerships In a world where access to essential healthcare is still a significant challenge, Project C.U.R.E. has teamed up with Microsoft to make a meaningful difference. This collaboration aims to change the lives of millions by providing vital medical resources to underserved populations. With over 4.5 billion people...
Continue Reading
How STRADVISION Is Leading the Charge in Automotive Innovation
Transforming the Automotive Industry: STRADVISION's Role STRADVISION, a pioneer in deep learning-based vision perception technology, is at the forefront of a revolution in the automotive industry. Their latest edition of the STRADVISION Market Intelligence Report delves into significant trends transforming the automotive landscape, influenced by advancements in autonomous...
Continue Reading
Holdings and Legal Developments: Atkore Inc. Class Action Insight
Understanding the Atkore Inc. Class Action Lawsuit In recent developments, Atkore Inc. (NASDAQ: ATKR) is facing a class action lawsuit that has raised significant attention among investors. The lawsuit, officially titled Westchester Putnam Counties Heavy & Highway Laborers Local 60 Benefits Fund v. Atkore Inc., highlights serious allegations against the company and its...
Continue Reading
Brenda Snow's Empowering New Book for Patients on Health Journey
Brenda Snow's Inspiring Book on Navigating Health Challenges Brenda Snow's upcoming book is generating buzz as a vital resource for individuals grappling with serious health issues. This essential guide, titled Diagnosed: The Essential Guide to Navigating the Patient's Journey, is set to empower patients and caregivers alike. A Personal Narrative That Inspires In her...
Continue Reading